What to Know About Trump’s Aide Natalie Harp
President Donald Trump and aide Natalie Harp (R) exit Marine One on the Ellipse near the White House on Aug.
16, 2026. —Mandel Ngan—AFP/Getty Images A previously little-known White House aide has garnered growing public attention in recent days after Sen.
Jon Ossoff mentioned her while levying an attack on President Donald Trump .
The Georgia Democrat said that Trump “doesn’t want to do the job” of President.
Instead, Ossoff continued, “He wants to build his ballroom and travel with Natalie.” Ossoff was referring to 35-year-old Natalie Harp, a longtime aide to Trump.
When asked about Ossoff’s comments, Trump likened the Democrat to “Pee-wee Herman” and said he “would much rather do other things.” Read More: CNN Condemns the White House’s Attacks on Journalist Kristen Holmes: Here’s What to Know So who is Harp, and what is her role in the White House? Here’s what to know.
Harp said that Trump saved her life In 2019, Harp went on Fox News and thanked Trump for signing the Right to Try law the year before.
She told the network that she had stage 2 bone cancer, and that the new law allowed her to access experimental treatments, which she said saved her life.
After hearing her recount her experience, Trump asked her to give a speech at the 2020 Republican National Convention, according to the New York Times .
“When I failed the chemotherapies that were on the market, no one wanted me in their clinical trials,” she said at the event.
“They didn’t give me the right to try experimental treatments, Mr.
President.
You did, and without you, I’d have died waiting for them to be approved.” But after the convention, the Washington Post reported that medical experts cast doubt on Harp’s claims.
Harp has said that she was treated with “an FDA-approved immunotherapy drug for an unapproved use,” and experts said that the federal legislation that Trump signed in 2018 wouldn’t have made that drug accessible to Harp because the medication had already been approved.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on time.com — the content belongs to TIME.